Gianni Bonadonna

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi request reprint The contribution of Gianni Bonadonna to the history of chemotherapy
    Domenico Ribatti
    Department of Human Anatomy and Histology, University of Bari Medical School, Piazza G Cesare, 11, Policlinico, 70124 Bari, Italy
    Cancer Chemother Pharmacol 60:309-12. 2007
  2. ncbi request reprint ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results
    Gianni Bonadonna
    Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    J Clin Oncol 22:2835-41. 2004
  3. ncbi request reprint Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer
    Gianni Bonadonna
    Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    J Clin Oncol 22:1614-20. 2004
  4. pmc 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
    Gianni Bonadonna
    Istituto Nazionale Tumori, 20133 Milan, Italy
    BMJ 330:217. 2005
  5. ncbi request reprint Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute
    Gianni Bonadonna
    Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Eur J Cancer 41:998-1006. 2005
  6. ncbi request reprint HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer
    Angela Moliterni
    Medical Oncology Unit, Department of Experimental Oncology, Scientific Direction, Istituto Nazionale Tumori, Italy
    J Clin Oncol 21:458-62. 2003
  7. ncbi request reprint Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
    Luca Gianni
    Istituto Nazionale Tumori, Milan, Italy, and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 11:8715-21. 2005
  8. doi request reprint Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence
    Romano Demicheli
    Department of Medical Oncology, IRCCS Foundation, National Cancer Institute, Milan, Italy
    Cancer Sci 101:826-30. 2010
  9. pmc Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour
    Romano Demicheli
    Istituto Nazionale Tumori, Milano, Italy
    Breast Cancer Res 6:R689-96. 2004
  10. ncbi request reprint Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial
    Lisa Licitra
    Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 21:327-33. 2003

Collaborators

Detail Information

Publications26

  1. ncbi request reprint The contribution of Gianni Bonadonna to the history of chemotherapy
    Domenico Ribatti
    Department of Human Anatomy and Histology, University of Bari Medical School, Piazza G Cesare, 11, Policlinico, 70124 Bari, Italy
    Cancer Chemother Pharmacol 60:309-12. 2007
    ..This review article summarizes the seminal work of the Italian scientist Gianni Bonadonna on the treatment of breast cancer and Hodgkin's disease.
  2. ncbi request reprint ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results
    Gianni Bonadonna
    Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    J Clin Oncol 22:2835-41. 2004
    ..Combined-modality approaches improved results compared with RT, but the optimal extent of RT fields when combined with chemotherapy warranted additional evaluation...
  3. ncbi request reprint Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer
    Gianni Bonadonna
    Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    J Clin Oncol 22:1614-20. 2004
    ..To assess the clinical relevance of different sequences of doxorubicin (DOX) and cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of disease relapse...
  4. pmc 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
    Gianni Bonadonna
    Istituto Nazionale Tumori, 20133 Milan, Italy
    BMJ 330:217. 2005
    ....
  5. ncbi request reprint Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute
    Gianni Bonadonna
    Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    Eur J Cancer 41:998-1006. 2005
    ..The main focus of future trials should be on reducing treatment sequelae to improve the quality of life of long-term survivors...
  6. ncbi request reprint HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer
    Angela Moliterni
    Medical Oncology Unit, Department of Experimental Oncology, Scientific Direction, Istituto Nazionale Tumori, Italy
    J Clin Oncol 21:458-62. 2003
    ..We address the issue of whether therapy regimens including CMF and ADM versus CMF alone have the same therapeutic effect in patients with HER2+ and HER2- tumors in terms of relapse-free survival (RFS) and overall survival (OS)...
  7. ncbi request reprint Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
    Luca Gianni
    Istituto Nazionale Tumori, Milan, Italy, and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 11:8715-21. 2005
    ..We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate...
  8. doi request reprint Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence
    Romano Demicheli
    Department of Medical Oncology, IRCCS Foundation, National Cancer Institute, Milan, Italy
    Cancer Sci 101:826-30. 2010
    ....
  9. pmc Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour
    Romano Demicheli
    Istituto Nazionale Tumori, Milano, Italy
    Breast Cancer Res 6:R689-96. 2004
    ..Information on the metastasis process in breast cancer patients undergoing primary tumour removal may be extracted from an analysis of the timing of clinical recurrence...
  10. ncbi request reprint Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial
    Lisa Licitra
    Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 21:327-33. 2003
    ..Here we repeat the results of a randomized, multicenter trial enrolling patients with a resectable, stage T2-T4 (> 3 cm), N0-N2, M0 untreated, squamous cell carcinoma of the oral cavity...
  11. ncbi request reprint Comment to Jatoi et al. report
    Romano Demicheli
    Department of Medical Oncology, Instituto Nazionale Tumori, Milano 20132, Italy
    Breast Cancer Res Treat 93:1-2. 2005
  12. doi request reprint Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer
    Luca Gianni
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    J Clin Oncol 27:2474-81. 2009
    ..To evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and to compare this combination with the same regimen given as primary systemic (neoadjuvant) therapy...
  13. ncbi request reprint Breast cancer
    Pinuccia Valagussa
    Istituto Nazionale Tumori, Milano, Italy
    Cancer Chemother Biol Response Modif 21:585-608. 2003
  14. ncbi request reprint Menopausal status dependence of early mortality reduction due to diagnosis of smaller breast cancers (T1 v T2-T3): relevance to screening
    Romano Demicheli
    Istituto Nazionale Tumori, Department of Medical Oncology, Via Venezian 1, 20137 Milan, Italy
    J Clin Oncol 22:102-7. 2004
    ..To provide data relevant to the paradoxical mortality excess for women age 40 to 49 years observed during the first 6 to 8 years in the invited group in all mammography screening studies...
  15. pmc Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients
    Michael Retsky
    Department of Surgical Research, Children s Hospital and Harvard Medical School, Boston, MA, USA
    Breast Cancer Res 6:R372-4. 2004
    ..We could imagine that it also plays a role in adjuvant chemotherapy effectiveness since, perhaps not coincidentally, this is most beneficial for premenopausal node-positive patients...
  16. ncbi request reprint CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome
    George Z Rassidakis
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1278-87. 2002
    ..Therefore, we correlated CD20 expression with presenting features and clinical outcome of untreated patients with classical HD...
  17. doi request reprint Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer
    Gianni Bonadonna
    Department of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori corrected
    J Clin Oncol 26:342-4. 2008
  18. ncbi request reprint Comment to "Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and intact primary tumor" by G V Babiera, R Rao, L Feng, F Meric-Bernstam, H M Kuerer, S E Singletary, K K Hunt, M I Ross, K M Gwyn, B W
    Romano Demicheli
    Ann Surg Oncol 14:1519-20. 2007
  19. ncbi request reprint Comment to Anderson WF, Jatoi I, Devesa SS: distinct breast cancer incidence and prognostic patterns in the NCI'S SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127-137, 2005
    Romano Demicheli
    Breast Cancer Res Treat 97:341-3. 2006
  20. ncbi request reprint Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus
    Paolo Bidoli
    Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer 94:352-61. 2002
    ..The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma...
  21. ncbi request reprint BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens
    George Z Rassidakis
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:3935-41. 2002
    ..We conclude that BCL-2 is frequently expressed by HRS cells in cHD and is associated with inferior FFS in patients treated with ABVD or equivalent regimens...
  22. ncbi request reprint Refined measurement of outcome for adjuvant breast carcinoma therapy
    John W Gamel
    Veterans Affairs Medical Center, Louisville, Kentucky, USA
    Cancer 97:1139-46. 2003
    ..This deficiency makes it difficult to determine the long-term difference in impact between the two treatment arms of a clinical trial...
  23. ncbi request reprint Breast cancer
    Pinuccia Valagussa
    Istituto Nazionale Tumori via Venezian 1 20133 Milan Italy
    Cancer Chemother Biol Response Modif 20:493-517. 2002
  24. ncbi request reprint Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy
    Carlo Visco
    Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, USA
    Leuk Lymphoma 45:2085-92. 2004
    ..0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT...
  25. ncbi request reprint Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome
    Marco Herling
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2114-20. 2003
    ..We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome...
  26. ncbi request reprint BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome
    George Z Rassidakis
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 8:488-93. 2002
    ..Therefore, we correlated BAX expression with presenting features and clinical outcome in untreated patients with HD...